MONECO Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.77M | Buy |
22,944
+4,946
| +27% | +$1.06M | 0.35% | 57 |
|
|
2026
Q1 | $3.91M | Sell |
17,998
-166
| -0.9% | -$36.8K | 0.3% | 71 |
|
|
2025
Q4 | $4.15M | Buy |
18,164
+892
| +5% | +$203K | 0.33% | 65 |
|
|
2025
Q3 | $4M | Buy |
17,272
+186
| +1% | +$37.9K | 0.33% | 61 |
|
|
2025
Q2 | $3.17M | Buy |
17,086
+272
| +2% | +$50.6K | 0.3% | 75 |
|
|
2025
Q1 | $3.52M | Sell |
16,814
-266
| -2% | -$51.7K | 0.36% | 60 |
|
|
2024
Q4 | $3.04M | Buy |
17,080
+2,586
| +18% | +$475K | 0.32% | 76 |
|
|
2024
Q3 | $2.86M | Buy |
14,494
+836
| +6% | +$156K | 0.36% | 78 |
|
|
2024
Q2 | $2.34M | Buy |
13,658
+1,265
| +10% | +$210K | 0.34% | 82 |
|
|
2024
Q1 | $2.26M | Buy |
12,393
+3,434
| +38% | +$592K | 0.36% | 80 |
|
|
2023
Q4 | $1.39M | Sell |
8,959
-995
| -10% | -$145K | 0.26% | 100 |
|
|
2023
Q3 | $1.48M | Buy |
9,954
+1,115
| +13% | +$164K | 0.4% | 61 |
|
|
2023
Q2 | $1.19M | Sell |
8,839
-295
| -3% | -$43.3K | 0.32% | 73 |
|
|
2023
Q1 | $1.46M | Buy |
9,134
+2,147
| +31% | +$328K | 0.43% | 55 |
|
|
2022
Q4 | $1.13M | Buy |
6,987
+24
| +0.3% | +$3.68K | 0.41% | 56 |
|
|
2022
Q3 | $934K | Buy |
6,963
+44
| +0.6% | +$6.31K | 0.37% | 66 |
|
|
2022
Q2 | $1.06M | Buy |
6,919
+274
| +4% | +$41.9K | 0.41% | 61 |
|
|
2022
Q1 | $1.08M | Sell |
6,645
-25
| -0.4% | -$3.63K | 0.4% | 56 |
|
|
2021
Q4 | $939K | Sell |
6,670
-209
| -3% | -$24.7K | 0.35% | 70 |
|
|
2021
Q3 | $742K | Buy |
6,879
+621
| +10% | +$71K | 0.29% | 80 |
|
|
2021
Q2 | $705K | Buy |
6,258
+78
| +1% | +$8.79K | 0.32% | 78 |
|
|
2021
Q1 | $669K | Buy |
6,180
+712
| +13% | +$76.2K | 0.33% | 77 |
|
|
2020
Q4 | $615K | Buy |
5,468
+583
| +12% | +$56K | 0.34% | 70 |
|
|
2020
Q3 | $428K | Buy |
4,885
+402
| +9% | +$37.8K | 0.27% | 85 |
|
|
2020
Q2 | $440K | Buy |
4,483
+284
| +7% | +$25K | 0.34% | 69 |
|
|
2020
Q1 | $320K | Buy |
4,199
+533
| +15% | +$45.4K | 0.33% | 76 |
|
|
2019
Q4 | $323K | Sell |
3,666
-100
| -3% | -$8.3K | 0.23% | 97 |
|
|
2019
Q3 | $285K | Buy |
3,766
+587
| +18% | +$40.2K | 0.22% | 96 |
|
|
2019
Q2 | $231K | Buy |
3,179
+176
| +6% | +$13.8K | 0.19% | 112 |
|
|
2019
Q1 | $242K | Buy |
3,003
+611
| +26% | +$50K | 0.2% | 111 |
|
|
2018
Q4 | $221K | Buy |
+2,392
| New | +$210K | 0.26% | 88 |
|
Other funds holding ABBV
MONECO Advisors's ABBV Position: Q2 2026 in Review
MONECO Advisors increased its AbbVie (ABBV) stake by 27% in Q2 2026, buying an estimated $1.06M and bringing the position to 22,944 shares worth $5.77M. The position accounts for 0.35% of the portfolio, ranked #57.
MONECO Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- MONECO Advisors held 22,944 shares of AbbVie worth $5.77M as of Q2 2026.
- MONECO Advisors bought 4,946 AbbVie shares in Q2 2026, an estimated $1.06M.
- AbbVie made up 0.35% of MONECO Advisors's portfolio in Q2 2026, its #57 holding.
- MONECO Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on MONECO Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.